Work

Infliximab and Vedolizumab Have Similar Clinical and Safety Outcomes Among Biologic-naïve Patients With Mild to Moderate Pediatric Inflammatory Bowel Disease.

Year: 2024

Type: article

Source: Gastroenterology

DOI: 10.1053/j.gastro.2023.11.231

Authors: Essam Elknawy, Michael Rosen, Ruben Colman, Alka Goyal

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4391242769

FWCI:

Cites:

Cited by:

Related to: 10